Home/Filings/4/0001209191-23-034699
4//SEC Filing

SOLAND DANIEL B 4

Accession 0001209191-23-034699

CIK 0001070494other

Filed

Jun 4, 8:00 PM ET

Accepted

Jun 5, 9:46 PM ET

Size

19.0 KB

Accession

0001209191-23-034699

Insider Transaction Report

Form 4
Period: 2021-06-22
Transactions
  • Exercise/Conversion

    Restricted Stock Units

    2021-06-223,0590 total
    Common Stock (3,059 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2023-06-018,5520 total
    Common Stock (8,552 underlying)
  • Award

    Director Stock Options (Right to Buy)

    2023-06-01+11,04511,045 total
    Exercise: $23.90Exp: 2033-05-31Common Stock (11,045 underlying)
  • Award

    Restricted Stock Units

    2023-06-01+6,6526,652 total
    Common Stock (6,652 underlying)
  • Exercise/Conversion

    Common Stock

    2023-06-01+8,55228,002 total
  • Exercise/Conversion

    Common Stock

    2021-06-22+3,05913,059 total
  • Exercise/Conversion

    Common Stock

    2022-06-07+6,39119,450 total
  • Exercise/Conversion

    Restricted Stock Units

    2022-06-076,3910 total
    Common Stock (6,391 underlying)
Footnotes (3)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of Acadia common stock.
  • [F2]The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date.
  • [F3]The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date.

Issuer

ACADIA PHARMACEUTICALS INC

CIK 0001070494

Entity typeother

Related Parties

1
  • filerCIK 0001318485

Filing Metadata

Form type
4
Filed
Jun 4, 8:00 PM ET
Accepted
Jun 5, 9:46 PM ET
Size
19.0 KB